Puerto Rico
-
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Phase 2 · randomised · 150 people · 5 sites in 3 countries · Recruiting now
-
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Phase 2 · randomised · 86 people · 286 sites in 2 countries · Running, not taking new patients
-
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Phase 3 · randomised · 712 people · 1,049 sites in 3 countries · Running, not taking new patients
-
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Phase 2 · randomised · 390 people · 59 sites in 14 countries · Recruiting now
-
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer
Phase 3 · randomised · 960 people · 1 site in Puerto Rico · Recruiting now
-
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Phase 3 · randomised · 800 people · 285 sites in 17 countries · Recruiting now
-
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Phase 2 · 225 people · 53 sites in 11 countries · Recruiting now
-
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation
Phase 3 · randomised · 461 people · 419 sites in 32 countries · Running, not taking new patients
-
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Phase 3 · randomised · 450 people · 291 sites in 35 countries · Recruiting now
-
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Phase 3 · randomised · 700 people · 250 sites in 26 countries · Recruiting now